Evicenter
Kisqali (ribociclib), All indications
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
26
Last updated

All questions

Safety: Kisqali (ribociclib), all indications

3 questions · 1 source

Warnings

What are the warnings and precautions for Kisqali?

“• Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life threatening, or fatal ILD/pneumonitis can occur with KISQALI treatment. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Interrupt and evaluate patients with new or worsening respiratory symptoms suspected to be due to ILD/pneumonitis. Permanently discontinue KISQALI in patients with recurrent symptomatic or severe ILD/pneumonitis. (2.2, 5.1) • Severe Cutaneous Adverse Reactions (SCARs): SCARs including Stevens- Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug- reaction with eosinophilia and systemic symptoms (DRESS) can occur with KISQALI treatment. Permanently discontinue KISQALI in patients with SCARs or other life-threatening cutaneous reactions. (2.2, 5.2) • QT Interval Prolongation: KISQALI has been shown to prolong the QT interval in a concentration-dependent manner. Monitor electrocardiograms (ECGs) and electrolytes prior to initiation of treatment with KISQALI. Repeat ECGs at approximately Day 14 of the first cycle, and as clinically indicated. Monitor electrolytes at the beginning of each cycle for 6 cycles, and as clinically indicated. Avoid using KISQALI with drugs known to prolong QT interval and/or strong CYP3A inhibitors. (2.2, 5.3, 7.1, 7.4) • Increased QT Prolongation with Concomitant Use of Tamoxifen: KISQALI is not indicated for concomitant use with tamoxifen. (5.4) • Hepatotoxicity: Increases in serum transaminase and bilirubin levels have been observed. Perform liver function tests (LFTs) before initiating treatment with KISQALI. Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. (2.2, 5.5) • Neutropenia: Perform complete blood count (CBC) before initiating therapy with KISQALI. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. (2.2, 5.6) • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception during therapy. (5.7, 8.1, 8.3)” (opens the source at this quote in a new tab)

Note: The passages are from the Highlights of the Prescribing Information.

What are the contraindications for Kisqali?

Can Kisqali cause severe skin reactions?